ZTS·Zoetis Inc.

Zoetis Inc. is a global leader in the animal health sector, developing and distributing a wide array of medicines, vaccines, and diagnostic products for both livestock and companion animals. Operating within the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry, Zoetis leverages its extensive product portfolio and innovation focus to address diverse animal health needs. The company's business model targets veterinarians, livestock producers, and pet owners, positioning it as a significant entity in the expanding animal health market. Analyzing Zoetis's recent earnings performance reveals a mixed trend. In Q4 2025, the company reported an actual EPS of $1.48 against an estimate of $1.616, and revenue of $2.387 billion against an estimate of $2.314 billion, indicating an EPS miss but a revenue beat. This followed Q3 2025, where actual EPS was $1.70 against an estimate of $1.6216, and revenue was $2.40 billion (revenue estimate not provided), showing an EPS beat. Prior to this, Q2 2025 saw actual EPS of $1.76 against an estimate of $1.61239, with revenue at $2.46 billion (revenue estimate not provided), marking an EPS beat. The most recent reported quarter, Q1 2026, showed an actual EPS of $1.53 against an estimate of $1.61537, and revenue of $2.262 billion against an estimate of $2.328 billion, indicating both an EPS and revenue miss. This pattern suggests recent deceleration in EPS performance, with a miss in the latest quarter after a series of beats. Historically, Zoetis has demonstrated a trajectory of growth, though recent quarters have presented challenges. The company has shown a pattern of beating revenue estimates when provided, but EPS performance has become more inconsistent, with misses in Q4 2025 and Q1 2026. Prior to these, the company had a streak of EPS beats in Q1 2025 and Q2 2025, indicating a recent shift in performance against analyst expectations. The revenue figures, where available, have generally shown positive year-over-year growth, but the recent EPS misses warrant attention. Recent news highlights significant developments impacting Zoetis. The company is under investigation for potential securities fraud, following a reduction in its outlook, which has raised concerns about management credibility and disclosure. This comes after a quarter where results fell short of expectations, attributed to increased pet owner price sensitivity, reduced veterinary traffic, and competition, leading to revised full-year guidance. Despite these headwinds, the FDA's emergency use authorization for Dectomax for screwworm treatment presents a potential positive for livestock parasiticides. Additionally, the company continues its regular dividend payments, signaling ongoing financial stability. Looking ahead, investors will be closely monitoring management's commentary at upcoming investor conferences for insights into the companion animal segment's recovery and any further challenges. The outcome of the securities fraud investigation will be a critical factor influencing investor confidence and governance. Furthermore, the company's ability to navigate competitive pressures and evolving consumer behavior in the pet care market will be key to watch in subsequent earnings reports.